Abstract 910
Background
Liver cancer is the fifth commonest cancer. As per the World Health Organization liver disease is the tenth most common cause of death in India. Among all liver cancers, Hepatocellular carcinoma (HCC) is the most frequent cause and comprises 90% of liver cancer. Liver cancer is one of the leading causes of death worldwide due to its aggressive nature and poor survival rate. Due to the advancement of new technologies, the demand of high quality of biological samples has increased for translational research and drug discovery. Biobank are a suitable place to get a high quality of annotated biosamples. Biobank are playing important role in the field of cancer research, diagnosis, prognosis, and treatment. Most of the Biobank are situated in economically developed countries while cancer and other related disease are more in developing countries. The Indian government has established a world-class National Liver Disease Biobank in 2017 with a capacity of 5.4 million samples. Its aim is to accelerate research and personalized treatment in India.
Methods
The Biobank has collaboration with different hospitals from all over India. It is following Decentralized collection, centralized storage, and informatics. All centers are collecting biosamples as per SOPs of National Liver Disease Biobank.
Results
The Biobank collects, process and store a wide array of biospecimens (tumor tissue, adjacent normal tissue, blood, plasma, serum, buffycoat……) using validated SOPs. At present Our Biobank has collaboration with three hospitals and four research centers. It has collected 2566 biosamples and has involved in many research projects.
Conclusions
Establishment of the biobank is a major step in liver cancer related clinical and basic research in India The aim of NLDB Biobank is to accelerate HCV, liver disease, and associated cancer research. It is a first and biggest Liver Biobank in India, have a network from different hospitals across the country. We have been involving in many research projects which results would be highly useful in patient care and cancer research, biomarker discovery and translational research.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
National Liver Disease Biobank.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
905 - Dose distribution in coronary arteries in left-sided breast cancer treated with Radiotherapy
Presenter: Umesh Velu
Session: Poster display - Cocktail
Resources:
Abstract
1060 - Metabolic Syndrome in Luminal-Type Non-Metastatic Breast Cancer during Hormonal Treatment Does it really have impact on prognosis?
Presenter: Kartika Taroeno-Hariadi
Session: Poster display - Cocktail
Resources:
Abstract
1148 - High Eosinophils Lymphocyte Ratio (ELR) Related With Subtype of Breast Cancer in Sanglah General Hospital, Bali
Presenter: Anak Agung Lestari
Session: Poster display - Cocktail
Resources:
Abstract
400 - Ribociclib (RIB) + endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC)
Presenter: Norikazu Masuda
Session: Poster display - Cocktail
Resources:
Abstract
801 - Osteopontin Level and Promoter Polymorphism is Associated with Aggressiveness in Breast Cancer
Presenter: Mohamed Elbaiomy
Session: Poster display - Cocktail
Resources:
Abstract
1014 - Global Clinical Trials Validating Bioequivalence with China-Manufactured Trastuzumab Biosimilar, HLX02, and Herceptin®
Presenter: Quanying Zhang
Session: Poster display - Cocktail
Resources:
Abstract
1138 - Circular RNA NCAPG promotes breast cancer metastasis through acting as the sponge of miR-200s
Presenter: Yunjie He
Session: Poster display - Cocktail
Resources:
Abstract
145 - Repeat biopsy a must in recurrent breast cancer: A study from tertiary cancer centre in India.
Presenter: Abhishek Anand
Session: Poster display - Cocktail
Resources:
Abstract
804 - Meta-analysis of four Phase 3 RCTs of tamoxifen, versus 3rd generation aromatase inhibitors as 1st Line Endocrine Therapy for HR+ Advanced Breast Cancer
Presenter: John Robertson
Session: Poster display - Cocktail
Resources:
Abstract
1154 - Estimation of efficacy and safety of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in recurrent or metastatic breast cancer patients
Presenter: Sung Soo Kang
Session: Poster display - Cocktail
Resources:
Abstract